Colombo, I;
Zaccarelli, E;
Del Grande, M;
Tomao, F;
Multinu, F;
Betella, I;
Ledermann, JA;
... Colombo, N; + view all
(2020)
ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies.
ESMO Open
, 5
, Article e000827. 10.1136/esmoopen-2020-000827.
Preview |
Text
Ledermann_ESMO management and treatment adapted recommendations in the COVID-19 era_VoR.pdf - Published Version Download (361kB) | Preview |
Abstract
The rapid spread of severe acute respiratory syndrome coronavirus 2 infection and its related disease (COVID-19) has required an immediate and coordinate healthcare response to face the worldwide emergency and define strategies to maintain the continuum of care for the non-COVID-19 diseases while protecting patients and healthcare providers. The dimension of the COVID-19 pandemic poses an unprecedented risk especially for the more vulnerable populations. To manage patients with cancer adequately, maintaining the highest quality of care, a definition of value-based priorities is necessary to define which interventions can be safely postponed without affecting patients' outcome. The European Society for Medical Oncology (ESMO) has endorsed a tiered approach across three different levels of priority (high, medium, low) incorporating information on the value-based prioritisation and clinical cogency of the interventions that can be applied for different disease sites. Patients with gynaecological cancer are at particular risk of COVID-19 complications because of their age and prevalence of comorbidities. The definition of priority level should be based on tumour stage and histology, cancer-related symptoms or complications, aim (curative vs palliative) and magnitude of benefit of the oncological intervention, patients' general condition and preferences. The decision-making process always needs to consider the disease-specific national and international guidelines and the local healthcare system and social resources, and a changing situation in relation to COVID-19 infection. These recommendations aim to provide guidance for the definition of deferrable and undeferrable interventions during the COVID-19 pandemic for ovarian, endometrial and cervical cancers within the context of the ESMO Clinical Practice Guidelines.
| Type: | Article |
|---|---|
| Title: | ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1136/esmoopen-2020-000827 |
| Publisher version: | http://dx.doi.org/10.1136/esmoopen-2020-000827 |
| Language: | English |
| Additional information: | © Author(s) (or their employer[s]) 2020. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license (http://creativecommons.org/licenses/by-nc/4.0/). |
| Keywords: | COVID-19, cervical cancer, endometrial cancer, ovarian cancer, value-based priorities |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10107448 |
Archive Staff Only
 |
View Item |
